Indirect comparison of efficacy and safety of chiglitazar and thiazolidinedione in patients with type 2 diabetes: A meta-analysis

Figure 3 The forest plot exhibiting pooled effect estimates and indirect comparison between chiglitazar and thiazolidinediones on safety endpoints including weight gain, hypoglycemia, edema, bone fractures, upper respiratory tract infection and urinary tract infection. HbA1c: Hemoglobin A1c; FBG: Fasting blood glucose; TG: Triglycerides; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High-density lipoprotein cholesterol; HOMA-IR: Homeostasis model assessment of insulin resistance; HOMA-β: Homeostasis model assessment of β cell function; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; RR: Risk ratios; 95%CI: 95% confidential intervals; TZD: Thiazolidinedione.